Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03271632 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Dec 31, 2026
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v10
  2. Primary completion date: Dec 31, 2019 to Dec 31, 2029
    • Start date: Jul 15, 2017 to Jun 1, 2026
    • Study sites: 2 to 1
    • Study completion date: Dec 31, 2020 to Dec 31, 2030
    v9
  3. Re-verified, no change to tracked fieldsv8
  4. Site contacts updated at 1 of 2 sitesv7
  5. Secondary endpoints: 1 to 2v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 1 to 2
    • Eligibility criteria shortened, about 10 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 8 words
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Eligibility criteria revised
    • Study description expanded, about 4 words
    v3
  4. Enrollment target: 10 to 20v2 Show 6 more changesShow less
    • Interventions: BCMA/CD38 CAR T cells (Biological) to CAR T cells (Biological)
    • Eligibility criteria shortened, about 79 words
    • Secondary endpoint revised
    • Primary endpoint revised
    • Study description shortened, about 6 words
    • Study title expanded, about 2 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
Trial Details
NCT Number NCT03271632
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov